United States - English - NLM (National Library of Medicine)

axia medical solutions, llc - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae) - dermesse balancer is indicated for the gradual bleaching of hyperpigmented skin conditions such as chlosma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation. prior history of sensitivity or allergic reaction to this product or any of its ingredients.  the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

United States - English - NLM (National Library of Medicine)

axia medical solutions, llc - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae) - dermesse skin lightener is indicated for the gradual bleaching of hyperpigmented skin conditions such as chlosma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation. prior history of sensitivity or allergic reaction to this product or any of its ingredients.  the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

Canada - English - Health Canada

university health network - gallium 68 ga oxodotreotide - solution - 122mbq - gallium 68 ga oxodotreotide 122mbq

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis : valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1) ].  prevention of cmv disease :valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2) ]. valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1) ].  risk summary after oral administrati

United States - English - NLM (National Library of Medicine)

northstar rx llc - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1) ]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2) ]. valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1) ]. risk summary after oral administration, val

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; stearic acid; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir viatris is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valganciclovir viatris is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - valganciclovir - film-coated tablet - valganciclovir 450 mg - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - valganciclovir - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg - film coated tablet - 450 mg - active: valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg excipient: crospovidone microcrystalline cellulose opadry brown 15b565009 purified water stearic acid - for the treatment of cytomegalovirus (cmv) retinitis in acquired immunodeficiency syndrome (aids) patients. for the prevention of cmv disease in solid organ transplant patients at risk.